Research and Markets: Prostate Cancer Drug Pathway Analyzer 2014

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/fk5ppr/prostate_cancer) has announced the addition of the "Prostate Cancer Drug Pathway Analyzer 2014" report to their offering.

There are today at least 386 targeted molecular therapies known to affect more than 244 specific intracellular signaling pathways for the treatment of prostate cancer. The rational for this plethora of treatment strategies is based on our increasing understanding of the 261 drug targets that are included in this drug-pathway analyzing tool. No less than 255 of these have been recorded with mutations and 46 drug targets have mutations which have been causally implicated in cancer.

Pathway Coverage

  • BioCarta # 244 Pathways
  • KEGG # 189 Pathways
  • NCI-Nature # 244 Pathways
  • NetPath # 32 Pathways

Pipeline Coverage

  • Marketed # 30
  • Pre-registration # 2
  • Phase III # 20
  • Phase II # 157
  • Phase I # 80
  • Preclinical # 121
  • No Data # 4
  • Suspended # 5
  • Ceased # 191

The continuous identification of drug targets and pathways that are altered in cancer is not only crucial for our understanding of cancer biology, but also to search for new targets for early diagnosis and improved treatment designs. Consequently, it has never before been as important to rapidly translate systems biology of disease and therapeutics to actionable pipeline decisions to ensure that the optimal market conditions exist by the time a candidate drug is commercialized.

Extra value: One year of free online updates included with this product.

For more information visit http://www.researchandmarkets.com/research/fk5ppr/prostate_cancer

Contacts

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Prostate Cancer

Sharing

Contacts

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Prostate Cancer